<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375033</url>
  </required_header>
  <id_info>
    <org_study_id>2014</org_study_id>
    <nct_id>NCT04375033</nct_id>
  </id_info>
  <brief_title>A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder</brief_title>
  <acronym>VA-BRAVE</acronym>
  <official_title>CSP #2014 - Comparative Effectiveness of Two Formulations of Buprenorphine for Treating Opioid Use Disorder in Veterans (VA-BRAVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly
      area) formulation of buprenorphine at a target dose of 300mg is superior in retaining
      Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily
      sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg
      (standard of care). This is an open-label, randomized, controlled trial including 900
      Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52
      weeks. There are a number of secondary objectives that will be studied as well and include:
      comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis C (HCV)
      testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of
      depression and posttraumatic stress disorder, housing status, and cost-effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CSP2014 is the first direct long-term comparison of monthly injectable versus daily SL
      buprenorphine. In addition to its impact on the care of Veterans, the results of VA-BRAVE
      will provide critical data to guide effective treatment of opioid use disorder throughout the
      United States.

      The CSP2014 study population is Veterans aged 18 years diagnosed with moderate to severe
      opioid use disorder (OUD)by Diagnostic and Statistical Manual (DSM)-5th edition criteria.
      Veterans must be entering a new episode of opioid use disorder care prior to study start.

      There are two primary outcomes that address key Veterans Health Administration (VHA) clinical
      issues related to opioid use disorder treatment. The first is retention on protocol-directed
      medication treatment (sublingual or injectable sub-cutaneous buprenorphine). The second
      primary outcome is opioid abstinence using the systematic Timeline Followback method of
      self-report and corresponding urine toxicology screens.

      VA-BRAVE includes a 52-week intervention and 52-week active assessment period, and up to a
      10-year passive follow-up for the duration of the study. Participants are inducted on daily
      SL buprenorphine using SAMHSA guidelines and dosed upward for a target dose of 16-24 mg for 3
      days (more than 3 days may be required if deemed clinically necessary; should not exceed 30
      days). Once reaching the target dose, participants are randomized 1:1 and assigned to receive
      at each 28-day research visit either: 1) a 28-day take-home supply of SL buprenorphine,
      prescribed at the clinically determined dose, or 2) injectable sub-cutaneous buprenorphine
      administered in the clinic (target dose = 300mg; 100mg dose may be used for those who cannot
      tolerate 300mg). Participants also receive Medication Management intervention at these
      visits.

      Study visits for all participants occur at Weeks 1, 2, 3 and 4 post-randomization, and
      biweekly thereafter through Week 52. Self-reported abstinence and urine toxicology screens
      are obtained at biweekly visits. Following one year of active follow-up, administrative data
      will be used to follow participants for up to 10 years for early enrollees and up to 7 years
      for late enrollees. The recruitment expectation is 15 new participants per study year per
      study site. There will be 20 participating VA Medical Center sites.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">August 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized 1:1 and assigned to receive at each 28-day research visit either: 1) a 28-day take-home supply of SL buprenorphine, prescribed at the clinically determined dose, or 2) injectable sub-cutaneous buprenorphine administered in the clinic (target dose = 300mg; 100mg dose may be used for those who cannot tolerate 300mg).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention in Treatment Change</measure>
    <time_frame>Approximately every 4 weeks until the first period of missed prescription medication coverage lasting at least 4 weeks through week 52</time_frame>
    <description>Measured by receipt of prescribed study drug (via prescription or admission) and assessed via local study team records. Retention-in-treatment is a highly sensitive indicator of effective treatment as discontinuation is strongly associated with recurrence of use to opioids and risk for accidental drug poisoning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Abstinence</measure>
    <time_frame>Approximately every 2 weeks through 52 weeks (active phase) and via EMR review for up to 10 years (passive phase)</time_frame>
    <description>Measured by Timeline Followback (self-report measure of substance use) and urine toxicology free of opioids. Both Timeline Followback and urine toxicology must indicate non-use to indicate abstinence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accidental Opioid Poisoning (overdose)</measure>
    <time_frame>Approximately every 2 weeks through 52 weeks (active phase) and via EMR review for up to 10 years (passive phase)</time_frame>
    <description>Self-reported non-fatal accidental opioid poisoning, hospital records, and CDC data on fatal accidental drug poisoning (by state) will be used to indicate fatal and non-fatal accidental opioid poisoning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) seroconversion</measure>
    <time_frame>Assessed at baseline, week 24, week 52 (active phase) and via EMR review for up to 10 years (passive phase)</time_frame>
    <description>Assessment will indicate positive seroconversion for HIV, HBV, or HCV based on HIV-1 p24 antigen/antibody with reflex HIV RNA viral load, HBV sAB, sAG with reflex HBV viral load if HBV sAG positive only, and HCV AB with reflex HCV viral load. These tests are recommended as standard care for Veterans with OUD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Assessed at baseline, weeks 12, 24, 36, and 52</time_frame>
    <description>Measure via the Veterans Rand-12, based on the 12-item Short Form Survey (SF12), a widely used measure of health-related quality of life. The VR-12 can be summarized resulting in a scale from 0 to 100, with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare and Service Utilization</measure>
    <time_frame>Assess from baseline approximately every 4 weeks through 52 weeks (active phase) and via EMR review for up to 10 years (passive phase)</time_frame>
    <description>An indicator of healthcare and service utilization will be obtained using the Service Utilization Review Form (SURF) that assesses utilization of VHA inpatient and outpatient care clinics, SUD clinics, detoxification programs, and pharmacies located within the VHA and local hospitals. Participants' use of other treatments will be documented on the SURF; non-VA health services will also be captured using the SURF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Opioid Use Disorder</condition>
  <arm_group>
    <arm_group_label>Sublingual Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sublingual buprenorphine contains naloxone in a ratio of 4:1 and will be prescribed. Consistent with the SAMHSA TIP 40 guidelines 75, before SL-BUP/NLX is prescribed, participants will be evaluated for recent (within 24 hours) drug use and associated symptoms.
The randomization dose will be determined based on the maintenance dose identified during the induction period, with a target dose of 16-24mg that is standard practice. While the target dose is 16-24mg, doses may go as low as 8mg as occasionally patients prefer lower doses. SL-BUP/NLX will be prescribed at the randomization visit (28-day supply), then every 4 weeks until week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injectable Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit. The target dose is 300mg, there is the option to use 100mg dose. The final study dose of injectable buprenorphine will be given at Week 48.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual buprenorphine with naloxone</intervention_name>
    <description>The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit.</description>
    <arm_group_label>Sublingual Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectable subcutaneous buprenorphine</intervention_name>
    <description>Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit.</description>
    <arm_group_label>Injectable Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has used opioids within 30 days prior to consent or within 30 days prior to entry into
             a supervised setting

               -  e.g., opioid use within the 30 days prior to recent (&lt;30 days) incarceration,
                  entry into a detoxification facility, or entry into an inpatient hospital setting

          -  Meets criteria for moderate to severe OUD based on the Mini-International
             Neuropsychiatric Interview

          -  Referred to/seeking treatment for OUD and willing to accept &quot;partial-agonist-based&quot;
             therapy

        Exclusion Criteria:

          -  Is a Veteran less than 18 years of age

          -  Has been taking a form of prescribed Medication-assisted treatment (MAT) continuously
             &gt;30 days prior to time of consent

          -  Has a history of significant adverse effects from buprenorphine and/or naloxone

          -  Has experienced recent suicidal ideation that requires hospitalization.

          -  Is unwilling or unable to provide consent

          -  Meets criteria for sedative hypnotic use disorder based on the MINI (Sedative Hypnotic
             Use Disorder)

          -  Has pending felony charges

          -  Is determined unsuitable for study participation based on the clinical judgement of
             the LSI or Co-I given results of a CIWA-Ar, physical exam, Liver function tests,
             kidney function tests, and CBC

          -  Is determined unsuitable for study participation based on observed prolonged QTc
             interval on an electrocardiogram (EKG)

          -  Has any other medical, psychiatric, behavioral, or logistical condition which, in the
             judgement of the LSI or Co-I, makes it unlikely the participant can participate in or
             complete the 52-week active phase of the study

          -  Is actively participating in an interventional clinical trial for which a waiver of
             dual-enrollment with CSP#2014 has not been obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismene L. Petrakis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia R Davis, PhD</last_name>
    <phone>(617) 483-5465</phone>
    <email>Cynthia.Davis8@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melynn Nuite, RN BS CCRC</last_name>
    <phone>(617) 232-9500</phone>
    <email>Melynn.Nuite@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System, Long Beach, CA</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ricardo Restrepo-Guzman, MD</last_name>
      <phone>562-826-8000</phone>
      <phone_ext>4684</phone_ext>
      <email>ricardo.restrepo-guzman@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Aliya Asghar, MPH</last_name>
      <phone>5628265212</phone>
      <email>aliya.asghar@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System, Palo Alto, CA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Ostacher, MD</last_name>
      <phone>650-849-0494</phone>
      <email>Michael.Ostacher@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Helle (Nicole) Nielsen</last_name>
      <email>Helle.NielsenBowles@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven Batki, MD</last_name>
      <phone>415-221-4810</phone>
      <phone_ext>23671</phone_ext>
      <email>steven.batki@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Brooke Lasher, MPH</last_name>
      <phone>4152214810</phone>
      <phone_ext>24495</phone_ext>
      <email>brooke.lasher@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CERC (VISN1, West Haven, CT)</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gihyun Yoon, MD</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>7421</phone_ext>
      <email>Gihyun.Yoon@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Abdul Kenja, RN</last_name>
      <phone>2039325711</phone>
      <email>Abdul.Kenja@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucy L Gu, PhD</last_name>
      <phone>215-939-5573</phone>
      <email>Lucy.Gu@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Ralevski, PhD</last_name>
      <phone>(203) 932-5711</phone>
      <phone_ext>4282</phone_ext>
      <email>Elizabeth.Ralevski@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Ismene L. Petrakis, MD</last_name>
      <role>Study Chair</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System, Pay Pines, FL</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Maha Lahoud-Bladykas, MD</last_name>
      <phone>727-398-6661</phone>
      <phone_ext>15898</phone_ext>
      <email>maha.lahoud-bladykas@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Lea Wescott, MBA</last_name>
      <phone>7273986661</phone>
      <phone_ext>15772</phone_ext>
      <email>Lea.Wescott@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System, Gainesville, FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lenardo Rodriguez, MD</last_name>
      <phone>352-548-6875</phone>
      <email>leonardo.rodriguez@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Hudleston, PA-C</last_name>
      <phone>3525487409</phone>
      <email>michelle.hudleston@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph Liberto, MD</last_name>
      <phone>410-605-7368</phone>
      <email>Joseph.Liberto@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Federline, MS</last_name>
      <phone>4106371433</phone>
      <email>Amanda.Federline@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John Renner, MD</last_name>
      <phone>617-248-1022</phone>
      <email>john.renner@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Diane Smedberg</last_name>
      <phone>7748263224</phone>
      <email>diane.smedberg@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John D. Dingell VA Medical Center, Detroit, MI</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicole Stromberg, MD</last_name>
      <email>Nicole.Stromberg@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Jones</last_name>
      <phone>313 5763277</phone>
      <email>Elizabeth.jones3@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Heather Swanson, MD</last_name>
      <phone>612-629-7543</phone>
      <email>heather.swanson@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Donyal Eret, BA</last_name>
      <phone>6126297215</phone>
      <email>donyal.eret@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Louis Stokes VA Medical Center, Cleveland, OH</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Youssef Mahfoud, MD</last_name>
      <phone>216-791-3800</phone>
      <phone_ext>66729</phone_ext>
      <email>youssef.mahfoud@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Pehek, PhD</last_name>
      <phone>2167913800</phone>
      <phone_ext>62181</phone_ext>
      <email>elizabeth.pehek@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dayton VA Medical Center, Dayton, OH</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45428</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shannon Miller, MD</last_name>
      <phone>513-423-8387</phone>
      <phone_ext>5650</phone_ext>
      <email>shannon.miller@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Donna Woerner, MSN</last_name>
      <phone>9372686511</phone>
      <phone_ext>3590</phone_ext>
      <email>donna.woerner@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Philadelphia MultiService Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kyle Kampman, MD</last_name>
      <phone>215-823-5343</phone>
      <email>kyle.kampman@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Derek A Giannone</last_name>
      <phone>215 8235800</phone>
      <phone_ext>202895</phone_ext>
      <email>derek.giannone@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven D Forman, MD</last_name>
      <phone>412-360-2295</phone>
      <email>steven.forman@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Pierce</last_name>
      <phone>4123602468</phone>
      <email>suzanne.pierce2@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Providence VA Medical Center, Providence, RI</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Swift, MD</last_name>
      <phone>401-457-3057</phone>
      <email>robert.swift@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Emily C Gagen, PhD</last_name>
      <phone>4012737100</phone>
      <phone_ext>3860</phone_ext>
      <email>emily.gagen@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Zakaria Zayour, MD</last_name>
      <phone>214-857-4477</phone>
      <email>zakaria.zayour@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Kenneth Murphy, BSN</last_name>
      <phone>2148573718</phone>
      <email>kenneth.murphy2@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle Bauer, MD</last_name>
      <phone>801-584-1217</phone>
      <email>Michelle.Bauer@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Kory Fleming, MPH</last_name>
      <phone>8015821565</phone>
      <phone_ext>3704</phone_ext>
      <email>Kory.Fleming@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hampton VA Medical Center, Hampton, VA</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23667</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ajay Manhapra, MD</last_name>
      <phone>757-722-9961</phone>
      <phone_ext>5916</phone_ext>
      <email>ajay.manhapra@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center, Salem, VA</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anjali Varma, MD</last_name>
      <phone>540-982-2463</phone>
      <phone_ext>3555</phone_ext>
      <email>anjali.varma@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Dunford, MS</last_name>
      <phone>5409822463</phone>
      <email>Kristin.Dunford@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clement J. Zablocki VA Medical Center, Milwaukee, WI</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295-1000</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Stohs, MD</last_name>
      <phone>414-384-2000</phone>
      <email>Matthew.Stohs@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Joan Banks, RN</last_name>
      <phone>4143842000</phone>
      <phone_ext>46836</phone_ext>
      <email>Joan.Banks@va.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Buprenorphine</keyword>
  <keyword>Veterans</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Abstinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

